Classement en actions
#17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Prix de l'action
$0.0416118
Capitalisation boursière
$12.78M
Changement (1 jour)
1.72%
Changement (1 an)
-22.01%
Échange Noxopharm Limited (NOX)
Nombre d'actions en circulation pour Noxopharm Limited (NOX)
Nombre d'actions en circulation au December 2025: 292.24M
Selon les derniers rapports financiers et le cours de l'action de Noxopharm Limited, le nombre actuel d'actions en circulation est de 292.24M. À la fin de June 2024, l'entreprise avait 292.26M actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Noxopharm Limited (NOX) de 2016 à 2026
Actions en circulation à la fin de chaque année
| Année |
Actions en circulation |
Changez |
|
2026 (TTM) |
292.24M |
-0.08%
|
|
2025 |
292.47M |
0.07%
|
|
2024 |
292.26M |
0.01%
|
|
2023 |
292.24M |
0.35%
|
|
2022 |
291.22M |
10.37%
|
|
2021 |
263.85M |
90.70%
|
|
2020 |
138.36M |
0.15%
|
|
2019 |
138.15M |
16.06%
|
|
2018 |
119.03M |
35.93%
|
|
2017 |
87.57M |
160.94%
|
|
2016 |
33.56M |
0.00%
|
Actions en circulation pour des entreprises similaires ou concurrentes
| Entreprise |
Actions en circulation |
Différence |
Pays |
|
|
4.45B |
1,422.00%
|
DK
|
|
|
253.90M |
-13.12%
|
US
|
|
|
102.90M |
-64.79%
|
US
|
|
|
190.00M |
-34.99%
|
BE
|
|
|
483.58M |
65.47%
|
AU
|
